董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David Baker | 男 | Director | 62 | 10.67万美元 | 0.13 | 2026-01-26 |
| W. Marc Hertz | 男 | President, Chief Executive Officer and Director | 56 | 102.72万美元 | 0.41 | 2026-01-26 |
| David Szekeres | 男 | Chair of the Board and Director | 52 | 20.42万美元 | 0.22 | 2026-01-26 |
| Roelof Rongen | 男 | Director | 60 | 12.42万美元 | 0.13 | 2026-01-26 |
| Camilla V. Simpson | 女 | Director | 54 | 13.12万美元 | 0.13 | 2026-01-26 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Leanne Kelly | 女 | Chief Financial Officer | 49 | 58.47万美元 | 0.16 | 2026-01-26 |
| W. Marc Hertz | 男 | President, Chief Executive Officer and Director | 56 | 102.72万美元 | 0.41 | 2026-01-26 |
| Vipin Kumar | 男 | Chief Scientific Officer | 66 | 57.91万美元 | 0.16 | 2026-01-26 |
| Albert Agro | 男 | Chief Medical Officer | 61 | 未披露 | 未持股 | 2026-01-26 |
董事简历
中英对照 | 中文 | 英文- David Baker
-
David Baker，曾担任Gri Bio, Inc.的成员。他于2019年1月15日至2019年8月23日担任董事会成员，并于2021年2月12日完成Gri Bio, Inc.普通股的首次公开发行后再次被任命为董事。他此前曾担任Vallon的总裁兼首席执行官（2019年1月15日至2023年4月12日）。自2018年1月15日被任命为Vallon’s之前。此前，他曾担任Alcobra Ltd.（现称为Arcturus）的临时首席执行官和首席商务官，在那里他监督ADAIR的发展。在加入Alcobra Ltd.之前，他在Shire Pharmaceuticals工作了10年，包括担任神经科学业务部的商业战略和新业务副总裁。在该职位上，他领导神经科学许可机会的商业评估，管理管道CNS产品的商业努力，并领导长期战略规划过程。此前，他曾担任Shire的Vyvanse的全球总经理，领导Vyvanse的推出，并领导全球扩张工作，包括在日本成功建立合作伙伴关系，并在加拿大和巴西推出。在此之前，他曾担任Shire的所有ADHD产品的营销副总裁。从1990年到2004年，他在默克公司（Merck & Co.）工作，在市场营销、销售、市场研究和业务发展方面担任越来越重要的职位。除了他在中枢神经系统药物方面的知识和经验外，他的专长还包括骨质疏松症、偏头痛和高脂血症的治疗。他直接参与了五种药物的营销，每种药物的年销售额超过10亿美元。他以优异成绩毕业于Duke University，获得经济学和计算机科学学士学位。他获得了Duke's Fuqua School of Business的市场营销工商管理硕士学位。他还担任私人医疗保健广告公司Benchworks, Inc.的董事会成员。
David Baker has served as a member of Board from January 15, 2019 until August 23, 2019, and upon the consummation of the initial public offering of Common Stock on February 12, 2021, he was again appointed as a director. He previoly served as Vallon's President and Chief Executive Officer from January 15, 2019 until April 12, 2023. Mr. Baker has also been serving as the President and Consultant of DB Biopharma Consulting LLC, a life science consulting company, since April 2023. He previoly served as the Interim Chief Executive Officer and Chief Commercial Officer of Alcobra Ltd. (now known as Arctur), where he oversaw the development of ADAIR. Prior to joining Alcobra Ltd., he worked at Shire Pharmaceuticals for 10 years, including as Vice President of Commercial Strategy and New Biness in the Neuroscience Biness Unit. In that role, Mr. Baker led the commercial assessment of neuroscience licensing opportunities, managed commercial efforts on pipeline central nervo system (CNS) products, and led the long term strategic planning process. Previoly, he served as Global General Manager for Shire's Vyvanse where he led the launch of Vyvanse and led global expansion efforts including successful establishment of a partnership in Japan and launches in Canada and Brazil. Prior to that, he served as Vice President of Marketing for all of Shire's ADHD products. From 1990 through 2004, Mr. Baker worked at Merck & Co., where he held positions of increasing responsibility in marketing, sales, market research, and biness development. In addition to his knowledge and experience with CNS medications, Mr. Baker's expertise includes therapeutics for osteoporosis, migraine, and hyperlipidemia. He has been directly involved with the marketing of five medications with annual sales in excess of $1.0 billion each. Mr. Baker graduated Magna Cum Laude with a bachelor's degree in Economics and Computer Science from Duke University. He earned a Master of Biness Administration in Marketing from Duke's Fuqua School of Biness. Mr. Baker also serves on the board of directors of Benchworks, Inc., a private healthcare advertising agency. - David Baker，曾担任Gri Bio, Inc.的成员。他于2019年1月15日至2019年8月23日担任董事会成员，并于2021年2月12日完成Gri Bio, Inc.普通股的首次公开发行后再次被任命为董事。他此前曾担任Vallon的总裁兼首席执行官（2019年1月15日至2023年4月12日）。自2018年1月15日被任命为Vallon’s之前。此前，他曾担任Alcobra Ltd.（现称为Arcturus）的临时首席执行官和首席商务官，在那里他监督ADAIR的发展。在加入Alcobra Ltd.之前，他在Shire Pharmaceuticals工作了10年，包括担任神经科学业务部的商业战略和新业务副总裁。在该职位上，他领导神经科学许可机会的商业评估，管理管道CNS产品的商业努力，并领导长期战略规划过程。此前，他曾担任Shire的Vyvanse的全球总经理，领导Vyvanse的推出，并领导全球扩张工作，包括在日本成功建立合作伙伴关系，并在加拿大和巴西推出。在此之前，他曾担任Shire的所有ADHD产品的营销副总裁。从1990年到2004年，他在默克公司（Merck & Co.）工作，在市场营销、销售、市场研究和业务发展方面担任越来越重要的职位。除了他在中枢神经系统药物方面的知识和经验外，他的专长还包括骨质疏松症、偏头痛和高脂血症的治疗。他直接参与了五种药物的营销，每种药物的年销售额超过10亿美元。他以优异成绩毕业于Duke University，获得经济学和计算机科学学士学位。他获得了Duke's Fuqua School of Business的市场营销工商管理硕士学位。他还担任私人医疗保健广告公司Benchworks, Inc.的董事会成员。
- David Baker has served as a member of Board from January 15, 2019 until August 23, 2019, and upon the consummation of the initial public offering of Common Stock on February 12, 2021, he was again appointed as a director. He previoly served as Vallon's President and Chief Executive Officer from January 15, 2019 until April 12, 2023. Mr. Baker has also been serving as the President and Consultant of DB Biopharma Consulting LLC, a life science consulting company, since April 2023. He previoly served as the Interim Chief Executive Officer and Chief Commercial Officer of Alcobra Ltd. (now known as Arctur), where he oversaw the development of ADAIR. Prior to joining Alcobra Ltd., he worked at Shire Pharmaceuticals for 10 years, including as Vice President of Commercial Strategy and New Biness in the Neuroscience Biness Unit. In that role, Mr. Baker led the commercial assessment of neuroscience licensing opportunities, managed commercial efforts on pipeline central nervo system (CNS) products, and led the long term strategic planning process. Previoly, he served as Global General Manager for Shire's Vyvanse where he led the launch of Vyvanse and led global expansion efforts including successful establishment of a partnership in Japan and launches in Canada and Brazil. Prior to that, he served as Vice President of Marketing for all of Shire's ADHD products. From 1990 through 2004, Mr. Baker worked at Merck & Co., where he held positions of increasing responsibility in marketing, sales, market research, and biness development. In addition to his knowledge and experience with CNS medications, Mr. Baker's expertise includes therapeutics for osteoporosis, migraine, and hyperlipidemia. He has been directly involved with the marketing of five medications with annual sales in excess of $1.0 billion each. Mr. Baker graduated Magna Cum Laude with a bachelor's degree in Economics and Computer Science from Duke University. He earned a Master of Biness Administration in Marketing from Duke's Fuqua School of Biness. Mr. Baker also serves on the board of directors of Benchworks, Inc., a private healthcare advertising agency.
- W. Marc Hertz
-
W. Marc Hertz，自2023年4月起担任Gri Bio，Inc.总裁兼首席执行官，并担任Gri Bio，Inc.董事会成员。2009年，他与他人共同创立了GRI Operations，自GRI Operations成立以来一直担任首席执行官和董事会主席。除了管理职位外，赫兹还曾于2005年至2009年在GemVax AS、2014年至2018年在Evozym Biologics Inc.以及自2008年以来在Multimeric Biotherapeutics担任董事。自1998年以来，赫兹博士还在生物技术行业的公司担任过多个高级职位。赫兹博士在鲍登学院获得生物学学士学位，在科罗拉多大学医学院获得免疫学和微生物学博士学位。
W. Marc Hertz has served as President and Chief Executive Officer and as a member of Board since April 2023. He co founded GRI Operations in 2009 and served as Chief Executive Officer and chairperson of its board of directors since its inception. In addition to his management positions, Dr. Hertz previoly served on the boards of directors of GemVax AS from 2005 to 2009, Evozym Biologics Inc., from 2014 to 2018, and currently serves on the board of directors of Multimeric Biotherapeutics, a privately held research and development biotechnology company, a position he has held since 2008. Dr. Hertz has also held several senior positions at companies in the biotechnology indtry since 1998, including Pharmexa, Inc., Pharmexa A/S and Multimeric Biotherapeutics, Inc. Dr. Hertz received his undergraduate degree in biology from Bowdoin College and his Ph.D. in immunology and microbiology from the University of Colorado Medical School. - W. Marc Hertz，自2023年4月起担任Gri Bio，Inc.总裁兼首席执行官，并担任Gri Bio，Inc.董事会成员。2009年，他与他人共同创立了GRI Operations，自GRI Operations成立以来一直担任首席执行官和董事会主席。除了管理职位外，赫兹还曾于2005年至2009年在GemVax AS、2014年至2018年在Evozym Biologics Inc.以及自2008年以来在Multimeric Biotherapeutics担任董事。自1998年以来，赫兹博士还在生物技术行业的公司担任过多个高级职位。赫兹博士在鲍登学院获得生物学学士学位，在科罗拉多大学医学院获得免疫学和微生物学博士学位。
- W. Marc Hertz has served as President and Chief Executive Officer and as a member of Board since April 2023. He co founded GRI Operations in 2009 and served as Chief Executive Officer and chairperson of its board of directors since its inception. In addition to his management positions, Dr. Hertz previoly served on the boards of directors of GemVax AS from 2005 to 2009, Evozym Biologics Inc., from 2014 to 2018, and currently serves on the board of directors of Multimeric Biotherapeutics, a privately held research and development biotechnology company, a position he has held since 2008. Dr. Hertz has also held several senior positions at companies in the biotechnology indtry since 1998, including Pharmexa, Inc., Pharmexa A/S and Multimeric Biotherapeutics, Inc. Dr. Hertz received his undergraduate degree in biology from Bowdoin College and his Ph.D. in immunology and microbiology from the University of Colorado Medical School.
- David Szekeres
-
David Szekeres，曾担任Gri Bio, Inc.的成员。自2009年4月起担任董事。Szekeres于2016年3月加入Heron Therapeutics, Inc.，担任首席运营官和财务主管。在此之前，他曾担任Regulus Therapeutics Inc.的首席商务官、首席财务官和总法律顾问（2014年至2016年）。从2008年到2014年2月被Thermo Fisher Scientific收购，他还担任Life Technologies Corporation的并购、证券和治理主管。2006年至2008年，他曾担任多家律师事务所（包括Latham & Watkins LLP）的公司律师。他目前担任Sanford Burnham Prebys的董事会成员。他从2014年3月起担任Edico Genome Inc.的董事会成员，直到2018年被Illumina收购；从2014年10月起担任Patara Pharma的董事会成员，直到2018年被Roivant Sciences收购。他持有加州大学欧文分校（University of California, Irvine）的犯罪学、法律和社会学士学位，以及杜克大学法学院（Duke University School of law）的法学博士学位。
David Szekeres was appointed as President in June 2024. Mr. Szekeres is an experienced life science executive with a proven track record of creating value with deep operational, commercial, corporate development/strategy, and legal expertise. Mr. Szekeres was most recently Executive Vice President and Chief Operating Officer of Heron Therapeutics, Inc. until 2023. Prior to joining Heron in 2016, he was the Chief Business Officer and General Counsel of Regulus Therapeutics, a clinical stage biotech company focused on RNA therapeutics and the Head of Mergers & Acquisitions at Life Technologies Corporation. Mr. Szekeres also holds positions as the Chair of the board of directors of GRI Bio, Inc. and is a member of the boards of directors of Colossal Biosciences Inc., CureMatch, Inc., and the Sanford Burnham Prebys Medical Discovery Institute. He received his J.D. from Duke University School of Law and earned his B.A. from the University of California, Irvine. - David Szekeres，曾担任Gri Bio, Inc.的成员。自2009年4月起担任董事。Szekeres于2016年3月加入Heron Therapeutics, Inc.，担任首席运营官和财务主管。在此之前，他曾担任Regulus Therapeutics Inc.的首席商务官、首席财务官和总法律顾问（2014年至2016年）。从2008年到2014年2月被Thermo Fisher Scientific收购，他还担任Life Technologies Corporation的并购、证券和治理主管。2006年至2008年，他曾担任多家律师事务所（包括Latham & Watkins LLP）的公司律师。他目前担任Sanford Burnham Prebys的董事会成员。他从2014年3月起担任Edico Genome Inc.的董事会成员，直到2018年被Illumina收购；从2014年10月起担任Patara Pharma的董事会成员，直到2018年被Roivant Sciences收购。他持有加州大学欧文分校（University of California, Irvine）的犯罪学、法律和社会学士学位，以及杜克大学法学院（Duke University School of law）的法学博士学位。
- David Szekeres was appointed as President in June 2024. Mr. Szekeres is an experienced life science executive with a proven track record of creating value with deep operational, commercial, corporate development/strategy, and legal expertise. Mr. Szekeres was most recently Executive Vice President and Chief Operating Officer of Heron Therapeutics, Inc. until 2023. Prior to joining Heron in 2016, he was the Chief Business Officer and General Counsel of Regulus Therapeutics, a clinical stage biotech company focused on RNA therapeutics and the Head of Mergers & Acquisitions at Life Technologies Corporation. Mr. Szekeres also holds positions as the Chair of the board of directors of GRI Bio, Inc. and is a member of the boards of directors of Colossal Biosciences Inc., CureMatch, Inc., and the Sanford Burnham Prebys Medical Discovery Institute. He received his J.D. from Duke University School of Law and earned his B.A. from the University of California, Irvine.
- Roelof Rongen
-
Roelof Rongen，自2023年4月起担任Gri Bio，Inc.董事会成员。荣恩先生自2022年7月起担任基因治疗公司Adolore BioTherapeutics的首席执行官，自2018年9月起担任AsteRx Pharma Consulting的管理合伙人，自2019年6月起担任Innovative Molecules的创始人/首席执行官。2012年，他创立了Matinas BioPharma（omega-3和脂质晶体纳米颗粒给药），并将其发展成为一家上市公司（纽约证券交易所代码：MTNB），直到2018年3月离职。荣恩先生是Humira和Lovaza等产品的开发和商业化不可或缺的一部分。在创立Matinas BioPharma之前，荣恩曾于2010年至2012年担任Trygg Pharma的执行副总裁，协助挪威Aker集团进入omega-3处方药业务，并最终出售给FMC。在加入Aker之前，Rongen先生是Reliant Pharmaceuticals（被葛兰素史克收购）的知识产权和投资组合管理副总裁，在那里他获得了Lovaza的许可，并领导了开发和上市前活动。在职业生涯早期，荣恩先生曾担任巴斯夫制药公司Humira和其他免疫学项目的全球产品总监（被雅培/艾伯维收购）。荣恩先生的职业生涯始于Arthur D. Little技术创新管理事务所的管理顾问，以及威尔克森集团（被IBM收购）的生物技术/制药顾问。荣恩先生获得了荷兰瓦赫宁根大学的分子科学（生物技术/生物工艺技术）工程学硕士学位和西北大学家乐氏商学院的MBA学位。
Roelof Rongen is a serial entrepreneur, company builder and Research and Development/Commercial Development leader with extensive experience across many therapeutic areas and functions. Mr. Rongen has served as Chief Executive Officer of Adolore BioTherapeutics, a gene-therapy company, since July 2022, Founder/Chief Executive Officer of Innovative Molecules since June 2019, and Managing Member of AsteRx Pharma Consulting since September 2018. In 2012, he founded and progressed Matinas BioPharma (omega-3 and lipid-crystal nano-particle drug delivery) into a public company (NYSE:MTNB) until his departure in March 2018. Prior to founding Matinas BioPharma, Mr. Rongen served as Executive Vice President at Trygg Pharma from 2010 to 2012 where he facilitated Norway's Aker Group's entry into the prescription omega-3 business, and ultimate sale to FMC. Mr. Rongen started his professional career as a management consultant at Arthur D. Little's Technology Innovation Management practice and as a biotechnology/pharmaceutical consultant at The Wilkerson Group (acquired by IBM). Mr. Rongen received a Master of Science in Engineering in Molecular Sciences (with Biotechnology/Bio-Process Technology focus) from Wageningen University in the Netherlands and a Master of Business Administration from the Kellogg Business School at Northwestern University. - Roelof Rongen，自2023年4月起担任Gri Bio，Inc.董事会成员。荣恩先生自2022年7月起担任基因治疗公司Adolore BioTherapeutics的首席执行官，自2018年9月起担任AsteRx Pharma Consulting的管理合伙人，自2019年6月起担任Innovative Molecules的创始人/首席执行官。2012年，他创立了Matinas BioPharma（omega-3和脂质晶体纳米颗粒给药），并将其发展成为一家上市公司（纽约证券交易所代码：MTNB），直到2018年3月离职。荣恩先生是Humira和Lovaza等产品的开发和商业化不可或缺的一部分。在创立Matinas BioPharma之前，荣恩曾于2010年至2012年担任Trygg Pharma的执行副总裁，协助挪威Aker集团进入omega-3处方药业务，并最终出售给FMC。在加入Aker之前，Rongen先生是Reliant Pharmaceuticals（被葛兰素史克收购）的知识产权和投资组合管理副总裁，在那里他获得了Lovaza的许可，并领导了开发和上市前活动。在职业生涯早期，荣恩先生曾担任巴斯夫制药公司Humira和其他免疫学项目的全球产品总监（被雅培/艾伯维收购）。荣恩先生的职业生涯始于Arthur D. Little技术创新管理事务所的管理顾问，以及威尔克森集团（被IBM收购）的生物技术/制药顾问。荣恩先生获得了荷兰瓦赫宁根大学的分子科学（生物技术/生物工艺技术）工程学硕士学位和西北大学家乐氏商学院的MBA学位。
- Roelof Rongen is a serial entrepreneur, company builder and Research and Development/Commercial Development leader with extensive experience across many therapeutic areas and functions. Mr. Rongen has served as Chief Executive Officer of Adolore BioTherapeutics, a gene-therapy company, since July 2022, Founder/Chief Executive Officer of Innovative Molecules since June 2019, and Managing Member of AsteRx Pharma Consulting since September 2018. In 2012, he founded and progressed Matinas BioPharma (omega-3 and lipid-crystal nano-particle drug delivery) into a public company (NYSE:MTNB) until his departure in March 2018. Prior to founding Matinas BioPharma, Mr. Rongen served as Executive Vice President at Trygg Pharma from 2010 to 2012 where he facilitated Norway's Aker Group's entry into the prescription omega-3 business, and ultimate sale to FMC. Mr. Rongen started his professional career as a management consultant at Arthur D. Little's Technology Innovation Management practice and as a biotechnology/pharmaceutical consultant at The Wilkerson Group (acquired by IBM). Mr. Rongen received a Master of Science in Engineering in Molecular Sciences (with Biotechnology/Bio-Process Technology focus) from Wageningen University in the Netherlands and a Master of Business Administration from the Kellogg Business School at Northwestern University.
- Camilla V. Simpson
-
Camilla V. Simpson，自2023年4月起担任Gri Bio，Inc.董事会成员。她自2017年10月起担任Spruce Biosciences董事会成员。自2021年4月以来，辛普森女士一直担任Zehna Therapeutics的首席执行官，这是一家处于早期阶段的生物技术公司，是克利夫兰诊所的衍生公司。自2019年4月以来，辛普森女士一直担任Rare Strategic，LLC的管理成员和总裁，为生物技术公司提供战略咨询和咨询服务。Simpson女士于2020年12月加入Dyve Biosciences董事会。从2017年4月到2019年4月，辛普森女士在BioMarin担任高级副总裁兼产品组合开发主管，负责公司和研发治理、项目领导、项目管理、竞争情报、组合战略和业务分析。2014年10月至2017年4月，辛普森女士担任BioMarin全球监管事务集团副总裁，2014年3月至2014年10月，辛普森女士担任BioMarin欧盟监管事务副总裁。她还在Shire工作了12年，在担任多个职务后，她的职责不断增加，最终担任监管事务早期发展和业务发展副总裁。辛普森女士拥有爱尔兰戈尔韦大学学院的理学学士学位和理学学士学位。英国金斯顿大学荣誉学位，英国伦敦大学理学硕士学位。
Camilla V. Simpson has served as a member of Board since April 2023. She has served as a member of Spruce Biosciences board of directors since October 2017. Since April 2021, Ms. Simpson has been Chief Executive Officer of Zehna Therapeutics, an early stage biotechnology company and a spin out from the Cleveland Clinic. Since April 2019, Ms. Simpson has been the Managing Member and President of Rare Strategic, LLC where she provides strategic advice and consulting services to biotechnology companies. Ms. Simpson joined the board of directors of Dyve Biosciences in December 2020. From April 2017 to April 2019, Ms. Simpson was SVP, Head of Product Portfolio Development at BioMarin where she was responsible for corporate and Research and Development governance, program leadership, project management, competitive intelligence, portfolio strategy, and biness analytics. From October 2014 to April 2017, Ms. Simpson was Group Vice President Global Regulatory Affairs at BioMarin, and from March 2014 to October 2014, Ms. Simpson was Vice President Regulatory Affairs EU at BioMarin. She also spent 12 years at Shire, where after multiple roles of increasing responsibility, ultimately held the position of Vice President of Regulatory Affairs Early Development and Biness Development. Ms. Simpson holds a Bachelor of Science from University College Galway, Ireland, a Bachelors of Science (Honors) from Kingston University, United Kingdom, and an Master of Science with distinction from University of London, UK. - Camilla V. Simpson，自2023年4月起担任Gri Bio，Inc.董事会成员。她自2017年10月起担任Spruce Biosciences董事会成员。自2021年4月以来，辛普森女士一直担任Zehna Therapeutics的首席执行官，这是一家处于早期阶段的生物技术公司，是克利夫兰诊所的衍生公司。自2019年4月以来，辛普森女士一直担任Rare Strategic，LLC的管理成员和总裁，为生物技术公司提供战略咨询和咨询服务。Simpson女士于2020年12月加入Dyve Biosciences董事会。从2017年4月到2019年4月，辛普森女士在BioMarin担任高级副总裁兼产品组合开发主管，负责公司和研发治理、项目领导、项目管理、竞争情报、组合战略和业务分析。2014年10月至2017年4月，辛普森女士担任BioMarin全球监管事务集团副总裁，2014年3月至2014年10月，辛普森女士担任BioMarin欧盟监管事务副总裁。她还在Shire工作了12年，在担任多个职务后，她的职责不断增加，最终担任监管事务早期发展和业务发展副总裁。辛普森女士拥有爱尔兰戈尔韦大学学院的理学学士学位和理学学士学位。英国金斯顿大学荣誉学位，英国伦敦大学理学硕士学位。
- Camilla V. Simpson has served as a member of Board since April 2023. She has served as a member of Spruce Biosciences board of directors since October 2017. Since April 2021, Ms. Simpson has been Chief Executive Officer of Zehna Therapeutics, an early stage biotechnology company and a spin out from the Cleveland Clinic. Since April 2019, Ms. Simpson has been the Managing Member and President of Rare Strategic, LLC where she provides strategic advice and consulting services to biotechnology companies. Ms. Simpson joined the board of directors of Dyve Biosciences in December 2020. From April 2017 to April 2019, Ms. Simpson was SVP, Head of Product Portfolio Development at BioMarin where she was responsible for corporate and Research and Development governance, program leadership, project management, competitive intelligence, portfolio strategy, and biness analytics. From October 2014 to April 2017, Ms. Simpson was Group Vice President Global Regulatory Affairs at BioMarin, and from March 2014 to October 2014, Ms. Simpson was Vice President Regulatory Affairs EU at BioMarin. She also spent 12 years at Shire, where after multiple roles of increasing responsibility, ultimately held the position of Vice President of Regulatory Affairs Early Development and Biness Development. Ms. Simpson holds a Bachelor of Science from University College Galway, Ireland, a Bachelors of Science (Honors) from Kingston University, United Kingdom, and an Master of Science with distinction from University of London, UK.
高管简历
中英对照 | 中文 | 英文- Leanne Kelly
Leanne Kelly自2021年5月起担任公司首席财务官。加入Vallon之前，她最近担任OptiNose，Inc（一家收入5000万美元的专业制药公司）的财务总监兼执行董事，负责全球财务报告。在她的职业生涯中，她在私人和上市公司担任财务高级副总裁、财务总监和首席财务官职位。Kelly女士的职业生涯始于担任毕马威会计师事务所的审计师。Kelly女士在利哈伊大学获得了商业经济学学士学位，专注于会计，并且是宾夕法尼亚州注册会计师的非活跃状态。
Leanne Kelly has served as Chief Financial Officer since the closing of the Merger in April 2023. From May 2021 until the closing of the Merger, she served as the Chief Financial Officer of Vallon. From 2016 to 2021, she served as the Controller and Executive Director of Global Financial Reporting at OptiNose, Inc., a multi million dollar revenue specialty pharmaceutical company. Over the cse of her career, she has held Senior Vice President of Finance, Controller and Chief Financial Officer positions in private and public companies such as Flor Orthopedics, Iroko Pharmaceuticals, LLC, and Genaera Corporation. Ms. Kelly began her career as an auditor with KPMG LLP. While serving in those roles, Ms. Kelly's work included multi million dollar financings, M&A diligence and support. She also has experience in financial oversight, internal and external financial reporting, forecasting, and financial analysis, as ll as investor and public relations. Ms. Kelly received her Bachelor of Science degree in Biness Economics with a concentration in Accounting from Lehigh University and is a licensed CPA (inactive stat) in the state of Pennsylvania.- Leanne Kelly自2021年5月起担任公司首席财务官。加入Vallon之前，她最近担任OptiNose，Inc（一家收入5000万美元的专业制药公司）的财务总监兼执行董事，负责全球财务报告。在她的职业生涯中，她在私人和上市公司担任财务高级副总裁、财务总监和首席财务官职位。Kelly女士的职业生涯始于担任毕马威会计师事务所的审计师。Kelly女士在利哈伊大学获得了商业经济学学士学位，专注于会计，并且是宾夕法尼亚州注册会计师的非活跃状态。
- Leanne Kelly has served as Chief Financial Officer since the closing of the Merger in April 2023. From May 2021 until the closing of the Merger, she served as the Chief Financial Officer of Vallon. From 2016 to 2021, she served as the Controller and Executive Director of Global Financial Reporting at OptiNose, Inc., a multi million dollar revenue specialty pharmaceutical company. Over the cse of her career, she has held Senior Vice President of Finance, Controller and Chief Financial Officer positions in private and public companies such as Flor Orthopedics, Iroko Pharmaceuticals, LLC, and Genaera Corporation. Ms. Kelly began her career as an auditor with KPMG LLP. While serving in those roles, Ms. Kelly's work included multi million dollar financings, M&A diligence and support. She also has experience in financial oversight, internal and external financial reporting, forecasting, and financial analysis, as ll as investor and public relations. Ms. Kelly received her Bachelor of Science degree in Biness Economics with a concentration in Accounting from Lehigh University and is a licensed CPA (inactive stat) in the state of Pennsylvania.
- W. Marc Hertz
W. Marc Hertz，自2023年4月起担任Gri Bio，Inc.总裁兼首席执行官，并担任Gri Bio，Inc.董事会成员。2009年，他与他人共同创立了GRI Operations，自GRI Operations成立以来一直担任首席执行官和董事会主席。除了管理职位外，赫兹还曾于2005年至2009年在GemVax AS、2014年至2018年在Evozym Biologics Inc.以及自2008年以来在Multimeric Biotherapeutics担任董事。自1998年以来，赫兹博士还在生物技术行业的公司担任过多个高级职位。赫兹博士在鲍登学院获得生物学学士学位，在科罗拉多大学医学院获得免疫学和微生物学博士学位。
W. Marc Hertz has served as President and Chief Executive Officer and as a member of Board since April 2023. He co founded GRI Operations in 2009 and served as Chief Executive Officer and chairperson of its board of directors since its inception. In addition to his management positions, Dr. Hertz previoly served on the boards of directors of GemVax AS from 2005 to 2009, Evozym Biologics Inc., from 2014 to 2018, and currently serves on the board of directors of Multimeric Biotherapeutics, a privately held research and development biotechnology company, a position he has held since 2008. Dr. Hertz has also held several senior positions at companies in the biotechnology indtry since 1998, including Pharmexa, Inc., Pharmexa A/S and Multimeric Biotherapeutics, Inc. Dr. Hertz received his undergraduate degree in biology from Bowdoin College and his Ph.D. in immunology and microbiology from the University of Colorado Medical School.- W. Marc Hertz，自2023年4月起担任Gri Bio，Inc.总裁兼首席执行官，并担任Gri Bio，Inc.董事会成员。2009年，他与他人共同创立了GRI Operations，自GRI Operations成立以来一直担任首席执行官和董事会主席。除了管理职位外，赫兹还曾于2005年至2009年在GemVax AS、2014年至2018年在Evozym Biologics Inc.以及自2008年以来在Multimeric Biotherapeutics担任董事。自1998年以来，赫兹博士还在生物技术行业的公司担任过多个高级职位。赫兹博士在鲍登学院获得生物学学士学位，在科罗拉多大学医学院获得免疫学和微生物学博士学位。
- W. Marc Hertz has served as President and Chief Executive Officer and as a member of Board since April 2023. He co founded GRI Operations in 2009 and served as Chief Executive Officer and chairperson of its board of directors since its inception. In addition to his management positions, Dr. Hertz previoly served on the boards of directors of GemVax AS from 2005 to 2009, Evozym Biologics Inc., from 2014 to 2018, and currently serves on the board of directors of Multimeric Biotherapeutics, a privately held research and development biotechnology company, a position he has held since 2008. Dr. Hertz has also held several senior positions at companies in the biotechnology indtry since 1998, including Pharmexa, Inc., Pharmexa A/S and Multimeric Biotherapeutics, Inc. Dr. Hertz received his undergraduate degree in biology from Bowdoin College and his Ph.D. in immunology and microbiology from the University of Colorado Medical School.
- Vipin Kumar
Vipin Kumar Chaturvedi自2023年4月起担任Gri Bio，Inc.首席科学官。2009年，他与他人共同创立了GRI Operations，自成立以来，一直担任GRI董事会成员和科学顾问委员会主席。Chaturvedi博士曾于2009年至2017年和2022年至2023年4月担任GRI Operations的首席科学官。Chaturvedi博士自2015年4月起担任加州大学圣迭戈分校免疫调节实验室医学教授。2015年，查图尔维迪博士与他人共同创立了模拟软件公司Simomics，英国，并在2015年至2022年7月期间担任非执行董事。此外，Chaturvedi博士自2009年以来一直担任咨询公司Vidur Discoveries，LLC的董事会成员。Chaturvedi博士在印度坎普尔大学获得生物学学士学位，在印度医学教育与研究所获得生物化学、分子生物学和免疫学硕士学位，在印度科学研究所获得生物化学博士学位
Vipin Kumar has served as Chief Scientific Officer since April 2023. He co founded GRI Operations in 2009 and, since its inception and until the date of the Merger, served as a member of its board of directors and as chairperson of its scientific advisory board. Dr. Kumar served as GRI Operations' Chief Scientific Officer from 2009 to 2017 and from 2022 to April 2023. Dr. Kumar has served as a Professor of Medicine, Laboratory of Immune Regulation at the University of California, San Diego since April 2015. In 2015, Dr. Kumar co founded Simomics, UK, a simulation software company and served as a non executive director from 2015 to July 2022. Additionally, Dr. Kumar has served on the board of directors of Vidur Discoveries, LLC, a consulting company, since 2009. Dr. Kumar obtained his undergraduate degree in biology from the Kanpur University, India, his master's in biochemistry, molecular biology and immunology from the Institute of Medical Education & Research, India, and his Ph.D. in biochemistry from the Indian Institute of Science, India.- Vipin Kumar Chaturvedi自2023年4月起担任Gri Bio，Inc.首席科学官。2009年，他与他人共同创立了GRI Operations，自成立以来，一直担任GRI董事会成员和科学顾问委员会主席。Chaturvedi博士曾于2009年至2017年和2022年至2023年4月担任GRI Operations的首席科学官。Chaturvedi博士自2015年4月起担任加州大学圣迭戈分校免疫调节实验室医学教授。2015年，查图尔维迪博士与他人共同创立了模拟软件公司Simomics，英国，并在2015年至2022年7月期间担任非执行董事。此外，Chaturvedi博士自2009年以来一直担任咨询公司Vidur Discoveries，LLC的董事会成员。Chaturvedi博士在印度坎普尔大学获得生物学学士学位，在印度医学教育与研究所获得生物化学、分子生物学和免疫学硕士学位，在印度科学研究所获得生物化学博士学位
- Vipin Kumar has served as Chief Scientific Officer since April 2023. He co founded GRI Operations in 2009 and, since its inception and until the date of the Merger, served as a member of its board of directors and as chairperson of its scientific advisory board. Dr. Kumar served as GRI Operations' Chief Scientific Officer from 2009 to 2017 and from 2022 to April 2023. Dr. Kumar has served as a Professor of Medicine, Laboratory of Immune Regulation at the University of California, San Diego since April 2015. In 2015, Dr. Kumar co founded Simomics, UK, a simulation software company and served as a non executive director from 2015 to July 2022. Additionally, Dr. Kumar has served on the board of directors of Vidur Discoveries, LLC, a consulting company, since 2009. Dr. Kumar obtained his undergraduate degree in biology from the Kanpur University, India, his master's in biochemistry, molecular biology and immunology from the Institute of Medical Education & Research, India, and his Ph.D. in biochemistry from the Indian Institute of Science, India.
- Albert Agro
Albert Agro，自2023年4月起担任公司顾问，头衔为首席医疗官。他于2009年与他人共同创立了GRI Operations，并在2017年8月至2023年4月期间担任GRI Operations的顾问，头衔是首席医疗官。Agro博士自2021年4月起担任Columbia Therapeutics Inc.总裁兼首席执行官，在生物技术和制药行业拥有超过20年的经验，曾担任多个高级临床和开发职位，包括2018年3月至2021年4月担任Sublimity Therapeutics Inc.首席执行官，2012年6月至2016年9月担任Cynapsus首席医疗官。此外，Agro博士目前担任麦克马斯特大学病理学和分子医学系的助理教授。Agro博士获得麦克马斯特大学医学系免疫学博士学位。
Albert Agro has served as Chief Medical Officer since April 2023. He co founded GRI Operations in 2009 and served as a consultant to GRI Operations with the title Chief Medical Officer from August 2017 until April 2023. Dr. Agro has been serving as the Chief Executive Officer of Jocasta Neuroscience Inc. since June of 2024. He has also served as President and Chief Executive Officer of Columbia Therapeutics Inc. since April 2021 and has over 20 years of experience in the biotechnology and pharmaceutical indtries having held several senior clinical and development positions, including Chief Executive Officer of Sublimity Therapeutics Inc. from March 2018 to April 2021 and Chief Medical Officer at Cynaps from June 2012 to September 2016. Dr. Agro received his Ph.D. in immunology from the Department of Medicine at McMaster University.- Albert Agro，自2023年4月起担任公司顾问，头衔为首席医疗官。他于2009年与他人共同创立了GRI Operations，并在2017年8月至2023年4月期间担任GRI Operations的顾问，头衔是首席医疗官。Agro博士自2021年4月起担任Columbia Therapeutics Inc.总裁兼首席执行官，在生物技术和制药行业拥有超过20年的经验，曾担任多个高级临床和开发职位，包括2018年3月至2021年4月担任Sublimity Therapeutics Inc.首席执行官，2012年6月至2016年9月担任Cynapsus首席医疗官。此外，Agro博士目前担任麦克马斯特大学病理学和分子医学系的助理教授。Agro博士获得麦克马斯特大学医学系免疫学博士学位。
- Albert Agro has served as Chief Medical Officer since April 2023. He co founded GRI Operations in 2009 and served as a consultant to GRI Operations with the title Chief Medical Officer from August 2017 until April 2023. Dr. Agro has been serving as the Chief Executive Officer of Jocasta Neuroscience Inc. since June of 2024. He has also served as President and Chief Executive Officer of Columbia Therapeutics Inc. since April 2021 and has over 20 years of experience in the biotechnology and pharmaceutical indtries having held several senior clinical and development positions, including Chief Executive Officer of Sublimity Therapeutics Inc. from March 2018 to April 2021 and Chief Medical Officer at Cynaps from June 2012 to September 2016. Dr. Agro received his Ph.D. in immunology from the Department of Medicine at McMaster University.